Skip to content

Study · Animal study (in vivo) · rat · 1997

5 results

Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency.

De Gennaro Colonna V, Rossoni G, Bernareggi M, Müller EE, Berti F

Cardiologia (Rome, Italy)1 Nov 1997Cited by 11 (Europe PMC)

PMID9534309 (opens in a new tab)PepBankPUB-09534309
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin fully restored somatotropic function.

    In plain wordsIn rats with low growth hormone, hexarelin restored growth hormone function.

    Peptide
    Hexarelin
    Outcome
    IncreaseSomatotropic function in GH-deficient rats
    Study

    ratn: not reported in source

    Young male rats made GH deficient with anti-GHRH serum (GHRH-Ab) for 20 days
    Comparator
    Control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin (80 micrograms/kg, s.c. twice daily), administered for 15 days to GHRH-Ab-treated rats, fully restored the somatotropic function and reversed all the signs of cardiac and endothelial dysfunction.
    1 context sentence
    Summary · context
    The ability of hexarelin, a recently synthesized hexapeptide with a remarkable growth hormone (GH)-releasing activity, to reverse signs of cardiovascular dysfunction in GH-deficient animals was studied in young male rats made GH deficient by the administration of an anti-GH-releasing hormone serum (…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hearts from hexarelin-treated rats showed ischemic damage similar to that in control rats.

    In plain wordsIn rats with low growth hormone, hexarelin brought the heart's response to blocked blood flow back to that of control rats.

    Peptide
    Hexarelin
    Outcome
    DecreaseIschemia and reperfusion damage in isolated hearts
    Study

    ratn: not reported in source

    Young male rats made GH deficient with anti-GHRH serum (GHRH-Ab) for 20 days
    Comparator
    Control rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    In fact, in heart preparations from rats treated with hexarelin the trend of the ischemic damage was similar to that observed in control rats
    1 context sentence
    Summary · context
    The ability of hexarelin, a recently synthesized hexapeptide with a remarkable growth hormone (GH)-releasing activity, to reverse signs of cardiovascular dysfunction in GH-deficient animals was studied in young male rats made GH deficient by the administration of an anti-GH-releasing hormone serum (…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin reverted the rate of 6-keto-PGF1 alpha formation to control levels.

    In plain wordsIn rats with low growth hormone, hexarelin brought a blood-vessel marker back to control levels.

    Peptide
    Hexarelin
    Outcome
    Increase6-keto-PGF1 alpha formation (prostacyclin metabolite)
    Study

    ratn: not reported in source

    Young male rats made GH deficient with anti-GHRH serum (GHRH-Ab) for 20 days
    Comparator
    Control rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    both the rate of formation of 6-keto-PGF1 alpha and the vasopressor activity of angiotensin II were reverted to control levels
    1 context sentence
    Summary · context
    The ability of hexarelin, a recently synthesized hexapeptide with a remarkable growth hormone (GH)-releasing activity, to reverse signs of cardiovascular dysfunction in GH-deficient animals was studied in young male rats made GH deficient by the administration of an anti-GH-releasing hormone serum (…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin reverted the vasopressor activity of angiotensin II to control levels.

    In plain wordsIn rats with low growth hormone, hexarelin brought the blood-vessel response to angiotensin II back to control levels.

    Peptide
    Hexarelin
    Outcome
    DecreaseAngiotensin II vasopressor activity on coronary vessels
    Study

    ratn: not reported in source

    Young male rats made GH deficient with anti-GHRH serum (GHRH-Ab) for 20 days
    Comparator
    Control rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    both the rate of formation of 6-keto-PGF1 alpha and the vasopressor activity of angiotensin II were reverted to control levels
    1 context sentence
    Summary · context
    The ability of hexarelin, a recently synthesized hexapeptide with a remarkable growth hormone (GH)-releasing activity, to reverse signs of cardiovascular dysfunction in GH-deficient animals was studied in young male rats made GH deficient by the administration of an anti-GH-releasing hormone serum (…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin brought all endothelial function parameters into the normal range.

    In plain wordsIn rats with low growth hormone, hexarelin brought blood-vessel lining function back to the normal range.

    Peptide
    Hexarelin
    Outcome
    IncreaseEndothelial function parameters in aortic rings
    Study

    ratn: not reported in source

    Young male rats made GH deficient with anti-GHRH serum (GHRH-Ab) for 20 days
    Comparator
    Control rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    Furthermore, all the parameters of endothelial function were in the normal range.
    1 context sentence
    Summary · context
    The ability of hexarelin, a recently synthesized hexapeptide with a remarkable growth hormone (GH)-releasing activity, to reverse signs of cardiovascular dysfunction in GH-deficient animals was studied in young male rats made GH deficient by the administration of an anti-GH-releasing hormone serum (…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.